ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)

Project Information

ApTOLL

Grant agreement ID: 101163492

DOI

10.3030/101163492

Project closed

EC signature date 20 May 2024

Start date 1 January 2024

End date 31 March 2026

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 569 737,25

EU contribution

€ 2 498 816,00

Coordinated by

APTATARGETS SL
Spain

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis

Author(s): Beatriz Fernández‐Gómez, Miguel A. Marchena, David Piñeiro, Paula Gómez‐Martín, Estefanía Sánchez, Yolanda Laó, Gloria Valencia, Sonia Nocera, Rocío Benítez‐Fernández, Ana M. Castaño‐León, Alfonso Lagares, Macarena Hernández‐Jiménez, Fernando de Castro
Published in: British Journal of Pharmacology, Issue 181, 2024, ISSN 0007-1188
Publisher: Wiley
DOI: 10.1111/BPH.16399

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

Author(s): Alicia Aliena-Valero, Macarena Hernández-Jiménez, Mikahela A. López-Morales, Eva Tamayo-Torres, María Castelló-Ruiz, David Piñeiro, Marc Ribó, Juan B. Salom
Published in: Pharmaceutics, Issue 16, 2024, ISSN 1999-4923
Publisher: MDPI AG
DOI: 10.3390/PHARMACEUTICS16060741